A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia

BACKGROUND: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T...

Descripción completa

Detalles Bibliográficos
Autores principales: Korfi, K., Mandal, A., Furney, S. J., Wiseman, D., Somervaille, T. C. P., Marais, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516045/
https://www.ncbi.nlm.nih.gov/pubmed/25712455
http://dx.doi.org/10.1093/annonc/mdv110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516045/
https://www.ncbi.nlm.nih.gov/pubmed/25712455
http://dx.doi.org/10.1093/annonc/mdv110

Ejemplares similares